28 April, 2026
As the global respiratory community prepares to descend upon London this July, a palpable sense of transformation surrounds the upcoming European Respiratory Society (ERS) Cough Conference. Scheduled for 15–17 July, 2026, the event is being billed by organizers as a definitive “turning point” for a field that has historically struggled to gain the clinical legitimacy it deserves. With a record-breaking volume of abstract submissions and a curriculum that bridges the gap between raw neurobiology and bedside application, the conference promises to redefine how clinicians classify, understand, and treat chronic cough.
The Evolution of a Medical Discipline: From Symptom to Disease
For decades, chronic cough was relegated to the periphery of respiratory medicine—a frustrating, often dismissive symptom that patients endured and physicians struggled to manage. However, the ERS Cough Conference 2026 signals a definitive departure from this nihilistic approach.
Dr. Imran Satia, a leading expert in chronic cough and a pivotal member of the event’s organising committee, suggests that we are witnessing the birth of a new disease entity. “The ERS Cough Conference brings together the science, the people, and the ideas that will shape the next decade,” says Dr. Satia. “We are at a turning point. What was once dismissed as a mere symptom is now being recognized as a defined, treatable disease. We are moving from decades of observation into an era of meaningful intervention.”
The conference theme, "Chronic Cough as a Disease," is more than a slogan; it represents a fundamental recalibration of respiratory medicine. The focus is specifically on refractory and unexplained chronic cough (UCC)—conditions where patients suffer from debilitating, persistent irritation without a clear underlying diagnosis. By framing these as distinct disease entities driven by cough hypersensitivity and neuronal dysregulation, the medical community is finally moving toward formal disease ownership, standardized classification, and, most importantly, targeted therapy.
Chronology and Scope: A Journey Through the Science
The 2026 programme has been meticulously curated to guide attendees through the lifecycle of a patient’s journey. By moving away from traditional, siloed lecture formats, the committee has opted for a narrative approach that connects the dots between mechanistic research and clinical decision-making.
The Structure of the 2026 Programme
The conference is structured to take delegates through a comprehensive, step-by-step framework:
- Defining the Problem: Establishing the clinical burden of chronic cough and the necessity of the "disease" framework.
- Mechanistic Deep-Dives: Examining the neurobiology of cough hypersensitivity and the pathways involved in persistent irritation.
- Diagnostic Innovation: Leveraging digital monitoring and biomarker phenotyping to better categorize patient sub-populations.
- Therapeutic Horizon: Exploring the pipeline of novel pharmacological agents, from P2X3 signaling to peripheral and central neuromodulation.
Dr. Satia emphasizes that the strength of this year’s format lies in its integration. "We integrate state-of-the-art lectures, patient perspectives, and cutting-edge abstracts with interactive, hands-on discussions," he notes. "The goal is for delegates to leave not just with a theoretical understanding, but with actionable insights that they can immediately apply in their clinics."
Supporting Data: A Surge in Scientific Inquiry
The sheer volume of engagement for the 2026 symposium is, in itself, a data point that underscores the field’s rapid maturation. Following its transition from the London International Cough Symposium, the ERS Cough Conference has received a record number of abstract submissions. This influx of data serves as a barometer for the field’s health, indicating a surge in both industry-led innovation and academic discovery.
The programme highlights several key scientific pillars that are currently driving the field forward:
1. The Convergence of Biology and Innovation
While ATP and P2X3 signaling remain cornerstones of cough research, the 2026 agenda broadens the scope significantly. Researchers are now looking at more complex pathways, including:
- Central Neuromodulation: A major focus will be on opioid receptor pathways, such as the use of nalbuphine, which represents a promising shift in treating the neurological component of the cough reflex.
- Peripheral Agents: The emergence of sodium channel blockers, including Taplucainium, offers new avenues for localized treatment that minimizes systemic side effects.
2. Precision Medicine and Phenotyping
The shift toward "precision medicine" is perhaps the most significant development for clinicians. The conference will dedicate significant time to:
- Biomarker Development: Moving away from a "one-size-fits-all" treatment approach.
- Digital Cough Monitoring: Utilizing objective, real-world data to track patient progress and treatment efficacy.
- Phenotyping Subtypes: Identifying how refractory chronic cough manifests differently in patients with comorbidities like bronchiectasis and interstitial lung diseases (ILD).
Official Perspectives: Bridging Academic Science and Industry
One of the most anticipated elements of the conference is the dialogue between academic researchers and pharmaceutical innovators. In many respiratory fields, the gap between the lab bench and the pharmacy shelf can take years to bridge. At the ERS Cough Conference, this gap is being actively compressed.
Dr. Satia is particularly enthusiastic about this intersection. "The interaction between academic science and industry-led innovation is where we will start to see the real change for patients," he explains. "We are seeing a maturation of the field where we now have a clear disease construct, objective measurement tools, and a robust pipeline of therapies targeting different mechanisms."
By positioning these new therapeutic approaches alongside emerging neurobiological research, the conference serves as a catalyst for translational science. This is not merely an academic exercise; it is a strategic effort to bring sustainable, evidence-based treatments to a patient population that has long been underserved.
The Future: Implications for Clinical Practice
For the clinicians, early-career researchers, and scientists attending the event, the implications are profound. The conference is designed to be highly inclusive, ensuring that the next generation of respiratory experts is deeply embedded in the conversation.
Empowering Early Career Professionals
The committee has placed a strong emphasis on accessibility, particularly for early-career researchers. Through an extensive schedule of poster sessions, oral presentations, and interactive roundtable discussions, these professionals are being given a seat at the table to shape the next phase of discovery.
"The field is still evolving," says Dr. Satia. "There is a real, tangible opportunity for early-career clinicians and scientists to influence the future of clinical translation. We are transitioning from a period of observation to an area of active intervention and real, measurable impact."
Defining the Future of Care
The ultimate takeaway from the 2026 conference is the transition toward "disease ownership." By standardizing the diagnosis and treatment of refractory and unexplained chronic cough, the medical community is poised to alleviate the significant burden these patients face.
The conference sessions on cough hypersensitivity and neurobiology will provide the foundational knowledge required for modern practice, while the sessions on heterogeneity—specifically looking at cough within the context of ILD and bronchiectasis—will help clinicians navigate complex, multi-morbid patient cases.
Conclusion: A Call to Action
As the date for the ERS Cough Conference 2026 approaches, the message to the global respiratory community is clear: the era of dismissing chronic cough as an intractable annoyance is over. Through the integration of cutting-edge research, a commitment to precision medicine, and a collaborative spirit between academia and industry, the field is ready to tackle the challenge of refractory chronic cough head-on.
For those in the field, this is more than just another annual meeting; it is a watershed moment. Whether it is through the exploration of new sodium channel blockers or the refined classification of cough phenotypes, the 2026 ERS Cough Conference is setting the stage for a decade of discovery. The challenge for attendees will be to translate these high-level scientific breakthroughs into the daily reality of patient care, ensuring that the "turning point" discussed in London is felt in clinics across the globe.
For more information on the conference, to view the full programme, or to secure your place at this landmark event, visit the official ERS Cough Conference portal.
